Trilaciclib to prevent low blood cell counts in limited-stage small cell lung cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether taking trilaciclib alongside standard chemotherapy can help prevent low blood cell counts (myelosuppression) in people with limited-stage small cell lung cancer. It may help you stay stronger during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have limited-stage small cell lung cancer (cancer that is only in one lung and nearby lymph nodes).
- You must have fully recovered from any previous cancer surgery.
- Your tumor must be measurable or evaluable through scans or tests.
- You must be willing to sign a form saying you understand and agree to join the study.
- You cannot have extensive-stage small cell lung cancer (cancer that has spread widely).
- You must not have active heart disease, known allergies to the study drugs, or be pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
This trial tests whether the drug trilaciclib can reduce low blood cell counts caused by chemotherapy in people with Ewing's sarcoma. If you qualify, you may receive a medication that could help protect your bone marrow during treatment.
This trial tests an investigational drug called trilaciclib that is given before chemoradiation to help protect your bone marrow and reduce side effects like low blood counts. It is for people with a specific type of esophageal cancer who have finished their main treatment.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
This trial tests a drug called trilaciclib, given before chemotherapy, to see if it can protect your bone marrow and help prevent dangerous drops in blood cell counts. If you have head and neck cancer that has returned or spread and haven't had prior drug treatment, this might help you stay stronger during chemo.
This trial tests a drug that may help protect your bone marrow during chemotherapy, possibly reducing side effects like low blood counts. It is for people with certain advanced or recurrent solid tumors who are about to start a specific chemo regimen.
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.